ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 1249 • ACR Convergence 2023

    Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis

    Kaveh Ardalan1, Angel Davalos1, Hwanhee Hong1, Bryce Reeve1, Christoph Hornik1, M. Anthony Moody1, Donald Lloyd-Jones2, Eveline Wu3, Audrey Ward1, Rebecca Sadun4, Jeffrey Dvergsten5, Ann Reed6, Mark Connelly7 and Laura Schanberg1, 1Duke University School of Medicine, Durham, NC, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of North Carolina School of Medicine, Chapel Hill, NC, 4Duke University, Durham, NC, 5Duke University School of Medicine, Hillsborough, NC, 6Duke University School of Medicine, Chapel HIll, NC, 7Children's Mercy Kansas City / University of Missouri-Kansas City School of Medicine, Kansas City, MO

    Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) patients are at high risk for cardiovascular disease (CVD). The American Heart Association cardiovascular health (CVH) construct is…
  • Abstract Number: 1462 • ACR Convergence 2023

    Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Sara garcia Perez1, Jose-Maria Pego-Reigosa2, Irene Altabás González1, Norman Jiménez3, Victor Del campo Perez4, JULIA MARTINEZ BARRIO5, Maria Galindo-Izquierdo6, Jaime Calvo- Alén7, Esther Uriarte Isacelaya8, Eva Tomero Muriel9, Mercedes Freire González10, Victor Martinez-Taboada11, Paloma Vela12, Antonio Fernandez-Nebro13, Alejandro Olivé-Marqués14, Javier Narvaez15, Raúl Menor-Almagro16, Gregorio Santos Soler17, José Ángel Hernández Beriain18, Javier Manero ruiz19, Elena Aurrecoechea Aguinaga20, Oihane Ibarguengoitia-Barrena21, Carlos Montilla-Morales22, Gema Bonilla23, Vicente Torrente-Segarra24, Ana Paula Cacheda25, Maria J. García-Villanueva26, Clara Moriano Morales27, Concepción Fito Manteca28, Cristina Bohórquez29, Nuria Lozano Rivas30 and Iñigo Rúa-Figueroa31, 1Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 2Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 3IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 4Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 5Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 6Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 7Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 8Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 9Rheumatology, Hospital La Princesa, Madrid, Spain, 10Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 11Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 12Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, 13Hospital Regional Universitario de Málaga, Malaga, Spain, 14Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 15Hospital Universitario de Bellvitge, Barcelona, Spain, 16Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 17Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, 18Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 19Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, 20Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 21Galdakao-Usansolo University Hospital, Bilbao, Spain, 22Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 23Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 24Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 25Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, 26Hospital Ramón y Cajal, Madrid, Spain, 27Rheumatology, Hospital Universitario de León, León, Spain, 28Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, 29Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 30Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 31Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

    Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
  • Abstract Number: 2097 • ACR Convergence 2023

    Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque

    Natalia Guajardo-Jauregui1, Iris Colunga2, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Rosa Arvizu-Rivera3 and Jesus Alberto Cardenas-De la Garza4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico

    Background/Purpose: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are employed to assess the likelihood of experiencing…
  • Abstract Number: 2257 • ACR Convergence 2023

    Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)

    Konstantinos Parperis1 and Bikash Bhattarai2, 1University of Cyprus Medical School, Nicosia, Cyprus, 2Valleywisehealth, Phoenix, AZ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease associated with an increased risk of cardiovascular complications, including acute coronary syndrome (ACS). However, there…
  • Abstract Number: 0390 • ACR Convergence 2023

    Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

    George Karpouzas1, Bianca Papotti2, Sarah Ormseth3, Marcella Palumbo2, Elizabeth Hernandez3, Maria Pia Adorni4, Francesca Zimetti2, Matthew Budoff1 and Nicoletta Ronda2, 1Harbor-UCLA Medical Center, Torrance, CA, 2University of Parma, Department of Food and Drug, Parma, Italy, 3The Lundquist Institute, Torrance, CA, 4Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy

    Background/Purpose: Cholesterol efflux capacity (CEC) is the main antiatherogenic function of high-density lipoprotein (HDL). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol export from arterial macrophages…
  • Abstract Number: 0579 • ACR Convergence 2023

    Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes

    Liisa Hopia1, Anna Laveskog2, Dag Leonard3, Andreas Jonsen4, Johanna.T Gustafsson2, Iva Gunnarsson5, Agneta Zickert6, Gunnel Nordmark7, Anders Bengtsson4, Leonid Padyukov8, Johanna Sandling3, Ann-Christine Syvänen9, Lars Rönnblom3, Magnus Andersson1 and Elisabet Svenungsson6, 1Department of Clinical Neuroscience, Unit of Neurology, Karolinska Institutet och Karolinska Universitetssjukhuset, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 5Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 7Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 8Karolinska Institutet, Solna, Sweden, 9Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden

    Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…
  • Abstract Number: 0811 • ACR Convergence 2023

    Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study

    Natalie McCormick1, Chio Yokose2, Jie Wei3, Na Lu4, Deborah Wexler1, Mary De Vera5, J. Antonio Avina-Zubieta4, Yuqing Zhang6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Health Management Center, Xiangya Hospital Central South University, Changsha, China, 4Arthritis Research Canada, Vancouver, BC, Canada, 5University of British Columbia, Vancouver, BC, Canada, 6Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 7Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
  • Abstract Number: 1270 • ACR Convergence 2023

    Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients

    Natalia Guajardo-Jauregui1, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Iris Colunga2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

    Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
  • Abstract Number: 1466 • ACR Convergence 2023

    Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020

    Shreena Kamlesh Gandhi1, Abhiram Challa2, Sandhya Shri Kanniyaram3, Arnav Kamat4, Tejasri Polana5 and Kaleb Michaud6, 1Kansas University School of Medicine, Wichita, KS, 2KU School of Medicine, Wichita, KS, 3John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 4NYCH+H/Woodhull, New York, NY, 5Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, 6University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
  • Abstract Number: 2103 • ACR Convergence 2023

    Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

    George Karpouzas1, Bianca Papotti2, Sarah Ormseth3, Marcella Palumbo2, Elizabeth Hernandez3, Maria Pia Adorni4, Francesca Zimetti2, Matthew Budoff1 and Nicoletta Ronda2, 1Harbor-UCLA Medical Center, Torrance, CA, 2University of Parma, Department of Food and Drug, Parma, Italy, 3The Lundquist Institute, Torrance, CA, 4Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy

    Background/Purpose: High-density lipoprotein (HDL) eliminates cholesterol from atherosclerotic lesions, a function known as cholesterol efflux capacity (CEC). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol transfer…
  • Abstract Number: 2384 • ACR Convergence 2023

    Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group

    Lisa Rosenberg1, Larabe Farrukh1, Simrin Kooner1, Moiz Ehtesham1, Sumbal Wajid1, Ruben Peredo-Wende2 and Shannon Murawski1, 1Albany Medical Center, Albany, NY, 2Stratton VA Medical Center, Albany, NY

    Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…
  • Abstract Number: 0391 • ACR Convergence 2023

    Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis

    George Karpouzas1, Sarah Ormseth2, Piet Van Riel3, Elena Myasoedova4, Miguel A Gonzalez-Gay5, Alfonso Corrales6, Solbritt Rantapää-Dahlqvist7, Petros Sfikakis8, Patrick Dessein9, Linda Tsang9, Carol Hitchon10, Hani El Gabalawi10, Virginia Pascual Ramos11, Irazú Contreras Yañez12, Iris Colunga13, Dionicio A. Galarza-Delgado13, José Ramón Azpiri-López13, Silvia Rolefstad14, Anne Grete Semb15, Durga P Misra16, Ellen Margrethe Hauge17 and GEORGE KITAS18, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Torrance, CA, 3Radboud University Medical Center, Drunen, Netherlands, 4Mayo Clinic, Rochester, MN, 5IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 6Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 7Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 8National Kapodistrian University of Athens Medical School, Athens, Greece, 9University of Witwatersrand, Johannesburg, South Africa, 10University of Manitoba, Winnipeg, MB, Canada, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 12Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 13Hospital Universitario UANL, Monterrey, Mexico, 14Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, 15Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, 16Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 17Aarhus University Hospital, Aarhus, Denmark, 18The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
  • Abstract Number: 0580 • ACR Convergence 2023

    Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus

    Gayathri MS, Aishwarya Gopal, Molly Mary Thabah, Christina Mariaselvam, jaiveer Singh and Chengappa Kavadichanda, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

    Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality in systemic lupus erythematosus (SLE). Role of conventional risk scores which predict cardiovascular events, to…
  • Abstract Number: 0858 • ACR Convergence 2023

    Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis

    Benjamin Terrier1, Gregory Pugnet2, Marie-Emmanuelle Sirieix3, Thomas Quemeneur4, Xavier Puéchal5, Francois Maurier6, Antoine Néel7, YGAL BENHAMOU8, Bernard Bonnotte9, Jean Schmidt10, Adrien Michon3, Antoine Baudet11, Pierre Charles12, Fleur Cohen13, Claire De Moreuil14, Emanuelle Dernis15, Pauline Belenotti16, Marc Ruivard17, Olivier Aumaitre18, Olivier Fain19, Raphaele Seror20, Cécile-Audrey Durel21, Noémie Jourde-Chiche22, Estibaliz Lazaro23, Gilles Chironi24, Guillaume Armengol25, Jeremy Bellien25, Philippe Ravaud26, Gabriel Baron26 and Loic Guillevin27, 1Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, 2CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 3HEGP, Paris, France, 4CH Valenciennes, Valenciennes, France, 5National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 6Hôpitaux privés de Metz, Vaux / Frankreich, France, 7CHU Nantes, Nantes, France, 8rouen university hospital, Rouen, France, 9Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 10CHU Amiens, Amiens, France, 11CH Annecy, Annecy, France, 12Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 13Sorbonne Université, Paris, France, 14CHU de Brest, Brest, France, 15CH Le Mans, Le Mans, France, 16CHU Marseille, Marseille, France, 17CHU Clermont Ferrand, Clermont Ferrand, France, 18CHU Saint Antoine, Paris, France, 19Hopital SAINT ANTOINE APHP, Paris, France, 20University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 21CHU Lyon, Lyon, France, 22AP-HM, Marseille, France, 23Bordeaux Hospital University, Pessac, France, 24Monaco, Monaco, Monaco, 25CHU Rouen, Rouen, France, 26Paris Cité University, Paris, France, 27University Paris Descartes, Paris, France

    Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…
  • Abstract Number: 1280 • ACR Convergence 2023

    Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Joshua Baker2, Brian Sauer3, Grant Cannon4, Gary Kunkel5, Bryce Binstadt6, Amy Joseph7, K Wysham8, Aleksander Lenert9, Gail Kerr10, Andreas Reimold11, Michael Duryee1, Geoffrey Thiele1, Ted R Mikuls12 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6University of Minnesota, Minneapolis, MN, 7Washington University / St. Louis VA, St. Louis, MO, 8VA Puget Sound/University of Washington, Seattle, WA, 9University of Iowa, Iowa City, IA, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11University of Texas Southwestern Medical Center, Dallas, TX, 12Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The risk of aortic stenosis is increased in people with RA and valvular heart disease (VHD) is among the most over-represented causes of cardiovascular…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology